Clinical Trial Update: Dose-Ranging Study of the Bimatoprost Ocular Insert [Phase 2]

View source ↗

Summary

Phase 2 dose-ranging study of the bimatoprost ocular insert for open-angle glaucoma and ocular hypertension completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ocular Hypertension
• Open-angle Glaucoma

Drugs mentioned

• Bimatoprost ocular insert (bimatoprost)

Snippet

Sponsor: ForSight Vision5, Inc. | Conditions: Primary Open-Angle Glaucoma, Ocular Hypertension | Phase 2 | Status: COMPLETED | Results posted: 2020-06-04